CLINICAL_TRIALS
trial_result
· 2018-05-04
Clinical Trial Update: REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification [Phase 3]
Summary
Phase 3 trial REVEAL evaluated the lipid-modifying effects of anacetrapib in patients with atherosclerotic cardiovascular disease; results were posted in 2018.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: University of Oxford | Conditions: Atherosclerotic Cardiovascular Disease | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2018-05-04